Hi-Tech Pharmacal posts $3 million loss
AMITYVILLE, N.Y. Hi-Tech Pharmacal had $40.4 million in sales during its fiscal first quarter ended July 31, the generic drug maker said Thursday. The numbers amounted to a decrease of $3 million from the same period in 2009.
The bulk of the company’s sales came from generic drugs, which had sales of $32.3 million, a $4.4 million decrease from the year before. The decrease mostly resulted from declines in sales of the eye treatments dorzolamide and timolol ophthalmic solution, or dorzolamide ophthalmic solution, whose sales declined by $7.9 million because of a significant reduction in price. At the same time, sales increases of fluticasone propionate nasal spray helped offset the decline.
Sales for the ECR Pharmaceuticals division were $3.5 million, a $241,000 increase over the year before, resulting from higher sales of the Lodrane (brompheniramine) line of allergy drugs, despite a decrease in sales of the DexPak (dexamethasone) line of corticosteroids.
Midlothian Labs, which markets niche generic drugs, had sales of around $1 million, a $340,000 decrease from the year before, while sales for the Health Care Products division, which markets over-the-counter products, were $3.5 million, a $1.4 million increase from the year before.
Watson gets FDA approval for generic Yasmin
MORRISTOWN, N.J. The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals, the drug maker said Tuesday.
Watson announced the FDA’s approval of Zarah (drospirenone and ethinyl estradiol tablets) in the 3 mg/0.03 mg strength. The drug is a generic version of Bayer’s Yasmin.
Watson said it has started shipping the drug, though Bayer’s patent litigation suit against the company concerning the drug remains pending in the U.S. District Court for the Southern District of New York.
Yasmin and generic versions had sales of around $97 million during the 12 months ended in June, according to IMS Health.
H1N1 prompts increase in thorough hand-washing among Americans
MILWAUKEE Concerns about last year’s H1N1 virus have had an impact on Americans’ hand-washing habits, according to a national survey conducted by Bradley Corp.
In Bradley’s second Healthy Hand Washing survey, 50% of the 1,053 respondents said they "wash their hands more thoroughly or longer or more frequently" in public restrooms as a result of the H1N1 virus — that’s up from 45% in 2009 when the same question was asked.
According to the National Institute of Allergy and Infectious Diseases, adults average two to four colds a year, and children have about six to 10. In fact, the common cold is a leading cause of doctor visits and missed days from school and work.
Bradley’s Healthy Hand Washing survey was conducted online from July 7 to 15, 2010, and queried 1,053 American adults about their hand-washing habits in public restrooms. Participants were from around the country, ranged in age from 18 to 65 years and older, and the split between men and women was 46% and 54%, respectively.